Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Post by retiredcopon Dec 14, 2020 11:47am
148 Views
Post# 32099936

What to do with this waiting game

What to do with this waiting game A few days ago mole101 indicated that while waiting for PMN to make a move, there was opportunities in other stocks ... my distraction from PMN is Slam Resources .. SXL on the TS Venture exchange, small compnay that has the claims to previously un charted areas of New Brunswick.   I have played with mining stocks before and this one looked like a good opportunity in the near term.  Trading around the same as PMN is right now . 
The last news release by the company really got my attention. 


SLAM Exploration (SXL) has struck 3,955 grams of gold per tonne at its wholly owned Menneval gold project in New Brunswick.

At the site, the resource company found a mineralized quartz vein intersected over a strike length of 114 metres with 12 sites of visible gold.

Gold was detected in all 17 samples collected from vein 18 which was traced over a strike length of 114 meters. Assay results range from 1.22 to 3,955 grams of gold per tonne over widths ranging from 0.04 to 0.12 metre thick.

The company said at least 40 additional quartz veins were discovered as well.  The company also dug an additional five trenches and uncovered numerous quartz boulders, across the property's 10,460 hectares.

The exploration program is supported in part by a $30,000 contribution to the Menneval gold project under the New Brunswick Junior Mining Assistance Program.

According to the provincial government, The New Brunswick Junior Mining Assistance Program (NBJMAP) is a financial assistance program for private-sector Junior companies.

The province provides up to 50 per cent of eligible costs, within defined limits, for mineral exploration projects and is intended to increase the probability of finding economically viable mineral resources in New Brunswick.

<< Previous
Bullboard Posts
Next >>